NASDAQ: CYAD | Healthcare / Biotechnology / Belgium |
2.06 | +0.0300 | +1.48% | Vol 22.16K | 1Y Perf -50.61% |
Aug 11th, 2022 13:48 DELAYED |
BID | 2.00 | ASK | 2.12 | ||
Open | 2.12 | Previous Close | 2.03 | ||
Pre-Market | - | After-Market | - | ||
- - | - -% |
Target Price | 11.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 433.98 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 46.41 | |
Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 44.54 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
Price Range Ratio 52W % | 14.44 | Earnings Rating | Neutral | |
Market Cap | 46.54M | Earnings Date | 5th Aug 2022 | |
Alpha | -0.05 | Standard Deviation | 0.16 | |
Beta | 1.38 |
Today's Price Range 2.002.12 | 52W Range 1.515.32 | 5 Year PE Ratio Range -6.70-5.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | -15.57% | ||
1 Month | 24.85% | ||
3 Months | 22.43% | ||
6 Months | -40.46% | ||
1 Year | -50.61% | ||
3 Years | -83.52% | ||
5 Years | -95.10% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -29.29 | |||
ROE last 12 Months | -82.13 | |||
ROA (5Y Avg) | -22.04 | |||
ROA last 12 Months | -38.66 | |||
ROC (5Y Avg) | -45.95 | |||
ROC last 12 Months | -74.51 | |||
Return on invested Capital Q | -17.73 | |||
Return on invested Capital Y | -11.84 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.00 | ||||
0.99 | ||||
435.02K | ||||
- | ||||
-1.20 | ||||
-1.52 | ||||
0.90 | ||||
1.62 | ||||
18.08M | ||||
Forward PE | -2.59 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.40 | ||||
2.60 | ||||
0.04 | ||||
0.07 | ||||
-99.70 | ||||
Leverage Ratio | 1.90 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
100.00 | ||||
-263 946.00 | ||||
-247 654.00 | ||||
-180 441.00 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
-87.15 | ||||
67.90 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2019 QR | -1.58 | 10.73 | Positive |
12/2019 QR | -1.65 | -0.61 | Negative |
12/2022 FY | -1.04 | 3.70 | Positive |
12/2023 FY | -0.94 | 2.08 | Positive |
Next Report Date | - |
Estimated EPS Next Report | - |
Estimates Count | - |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 22.16K |
Shares Outstanding | 22.59K |
Shares Float | 22.59M |
Trades Count | 82 |
Dollar Volume | 46.10K |
Avg. Volume | 235.80K |
Avg. Weekly Volume | 97.42K |
Avg. Monthly Volume | 448.71K |
Avg. Quarterly Volume | 161.27K |
Celyad Oncology SA (NASDAQ: CYAD) stock closed at 2.06 per share at the end of the most recent trading day (a 1.48% change compared to the prior day closing price) with a volume of 22.16K shares and market capitalization of 46.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 107 people. Celyad Oncology SA CEO is Filippo Petti.
The one-year performance of Celyad Oncology SA stock is -50.61%, while year-to-date (YTD) performance is -43.72%. CYAD stock has a five-year performance of -95.1%. Its 52-week range is between 1.51 and 5.32, which gives CYAD stock a 52-week price range ratio of 14.44%
Celyad Oncology SA currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.99, a price-to-sale (PS) ratio of 435 018.00, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.66%, a ROC of -74.51% and a ROE of -82.13%. The company’s profit margin is -%, its EBITDA margin is -247 654.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Celyad Oncology SA, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Celyad Oncology SA’s next earnings report date is -.
The consensus rating of Wall Street analysts for Celyad Oncology SA is Strong Buy (1), with a target price of $11, which is +433.98% compared to the current price. The earnings rating for Celyad Oncology SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Celyad Oncology SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Celyad Oncology SA has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.17, ATR14 : 0.24, CCI20 : 43.64, Chaikin Money Flow : 0.34, MACD : 0.08, Money Flow Index : 92.05, ROC : 17.71, RSI : 51.73, STOCH (14,3) : 38.89, STOCH RSI : 0.28, UO : 46.43, Williams %R : -61.11), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Celyad Oncology SA in the last 12-months were:
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Moderate Buy | Moderate Buy |
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
CEO: Filippo Petti
Telephone: +32 10394100
Address: Rue Edouard Belin 2, Mont-Saint-Guibert 1435, , BE
Number of employees: 107
Mon, 28 Feb 2022 16:39 GMT Celyad (CYAD) Receives a Hold from JonesTrading
- TipRanks. All rights reserved.Mon, 28 Feb 2022 15:45 GMT Celyad (CYAD) was Downgraded to a Hold Rating at H.C. Wainwright
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.